Get involved – NICE consultation on duvelisib for relapsed or refractory CLL/SLL
Published on: 9 September 2021If you have CLL or SLL, let us know your experience of treatment and your views on potential future treatments by taking part in an online survey.
The National Institute for Health and Care Excellence (NICE) is carrying out an appraisal of a targeted drug called duvelisib, to decide whether or not it should be funded on the NHS for adults with CLL/SLL who have relapsed after at least two previous courses of treatment.
Along with our friends at Leukaemia Care and the CLL Support Association, we are taking part in the appraisal, representing the views of people affected by CLL/SLL. We aim to provide an insight into how CLL/SLL affects people’s everyday lives, and the impact duvelisib might have for people who are affected.
Leukaemia Care have put together an online survey to collect information that will help us put together a response that fully reflects the views of the CLL/SLL community. If you have CLL or SLL, have your say by completing the survey.
Posted: 9 September 2021